The startup develops a laparoscopically implantable medical device that utilizes a patient-specific molecular expression pattern to target receptors in the pancreas, enabling early intervention for type 2 diabetes. This technology aims to prevent complications associated with the disease by facilitating timely treatment.
Funding
$13.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for type 2 diabetes (T2D) often have limited long-term efficacy due to poor patient adherence, adverse side effects, and the invasive nature of metabolic surgeries, which only provide remission in a limited number of cases. Existing T2D treatments may also fail to address the underlying issue of deficient glucose receptors in the portal vein, hindering the brain's ability to regulate glucose metabolism effectively.
Solution
Paltech is developing a laparoscopically implantable medical device designed to upregulate deficient glucose receptors in the portal vein of T2D and obese patients, restoring the body's natural glucose regulation. By targeting the vagal nerve connection between these receptors and the brain, the device aims to stimulate insulin secretion by the pancreas, leading to sustained T2D remission. This approach offers a potential alternative or complement to existing treatments, with the goal of reducing medication dosages and associated side effects.
Target Audience
The primary target audience includes individuals with type 2 diabetes and obesity, as well as diabetologists and specialists seeking innovative treatment options.
Features
- Laparoscopically implantable device for minimally invasive delivery
- Designed to upregulate glucose receptors in the portal vein
- Aims to restore physiological glucose regulation via the vagal nerve
- Intended for long-term implantation
- Preclinical results demonstrate potential for sustained T2D remission